Results 1 to 10 of about 284,903 (195)

Experimental chemotherapy of schistosomiasis mansoni [PDF]

, 1977
In mice experimentally infected with Schistosoma mansoni, praziquantel (2-cyclohexylcarbonyl-1,3,4,6,7,11b-hexahydro-2H-pyrazino[2,1-a]isoquinoline-4-one), administered orally at the levels of 100 and 50 mg/kg, for 5 consecutive days, produced oogram changes in all animals and a pronounced hepatic shift of schistosomes (97.1 and 89.1, respectively). At
J. Pellegrino, Fernanda F. Lima-Costa, Miriam A. Carlos, R�mulo T. Mello   +3 more
openalex   +5 more sources

The Experimental Chemotherapy of Influenza Viruses [PDF]

The Journal of Immunology, 1954
Summary Twelve compounds were found to inhibit the PR8 strain of influenza A virus in embryonated eggs, and six of these also inhibited the Lee strain of influenza B. Four of the inhibitors were virucidal as shown by in vitro tests at concentrations similar to those existing in the allantoic cavity.
Kenneth K. Takemoto, Mary Louise Robbins, Paul K. Smith   +2 more
openalex   +3 more sources

Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies [PDF]

Memorias do Instituto Oswaldo Cruz, 2009
Chagas disease, which is caused by the intracellular parasite Trypanosoma cruzi, is a neglected illness with 12-14 million reported cases in endemic geographic regions of Latin America.
Maria de Nazaré C Soeiro, Andréia P Dantas, Anissa Daliry, Cristiane F da Silva, Denise GJ Batista, Elen M de Souza, Gabriel M Oliveira, Kelly Salomão, Marcos Meuser Batista, Michelle GO Pacheco, Patrícia Bernardino da Silva, Ricardo M Santa-Rita, Rubem FS Menna Barreto, David W Boykin, Solange Lisboa de Castro   +14 more
doaj   +2 more sources

The immune-dependence of chemotherapy in experimental schistosomiasis [PDF]

Memorias do Instituto Oswaldo Cruz, 1989
Experimental evidence indicates that immune effector mechanisms can enhance the activity of schistosomicidal drugs. Praziquantel, oxamniquine, hycanthone and antimony were less effective against Schistosoma mansoni infections in mice immunosuppressed by ...
M. J. Doenhoff
doaj   +6 more sources

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

npj Precision Oncology, 2022
Anaplastic lymphoma kinase (ALK) fusion is found in ~3%–5% of patients with non-small-cell lung cancers (NSCLCs). Although the third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib shows high clinical efficacy in ALK-positive NSCLC, most of the
Yuki Shimizu, Koutaroh Okada, Jun Adachi, Yuichi Abe, Ryohei Narumi, Ken Uchibori, Noriko Yanagitani, Sumie Koike, Satoshi Takagi, Makoto Nishio, Naoya Fujita, Ryohei Katayama   +11 more
doaj   +1 more source

The Impact of the CTHRSSVVC Peptide Upon Experimental Models of Trypanosoma cruzi Infection

Frontiers in Cellular and Infection Microbiology, 2022
Chagas disease (CD), caused by the hemoflagellate protozoan Trypanosoma cruzi, affects more than six million people worldwide and presents an unsatisfactory therapy, based on two nitroderivatives, introduced in clinical medicine for decades.
Gabriela Rodrigues Leite, Denise da Gama Jaén Batista, Ana Lia Mazzeti, Ana Lia Mazzeti, Rosemeire Aparecida Silva, Ademar Benévolo Lugão, Maria de Nazaré Correia Soeiro   +6 more
doaj   +1 more source

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity

npj Precision Oncology, 2021
Approximately 15–30% of patients with lung cancer harbor mutations in the EGFR gene. Major EGFR mutations (>90% of EGFR-mutated lung cancer) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). Many uncommon EGFR mutations have been identified,
Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Ryo Kanada, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Ryo Ariyasu, Satoru Kitazono, Hironori Ninomiya, Kengo Takeuchi, Noriko Yanagitani, Satoshi Takagi, Kazuma Kishi, Naoya Fujita, Yasushi Okuno, Makoto Nishio, Ryohei Katayama   +19 more
doaj   +1 more source

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Nature Communications, 2021
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung ...
Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama   +23 more
doaj   +1 more source

Lonidamine Causes Inhibition of Angiogenesis-Related Endothelial Cell Functions

Neoplasia: An International Journal for Oncology Research, 2004
The aim of this study was to assess whether lonidamine (LND) interferes with some steps in angiogenesis progression. We report here, for the first time, that LND inhibited angiogenic-related endothelial cell functions in a dose-dependent manner (1-50 μg ...
Donatella Del Bufalo, Daniela Trisciuoglio, Marco Scarsella, Giulia D'Amati, Antonio Candiloro, Angela Iervolino, Carlo Leonetti, Gabriella Zupi   +7 more
doaj   +1 more source

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

Thoracic Cancer, 2020
Background Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of non‐small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK‐positive NSCLCs. However, the emergence of acquired resistance is inevitable.
Ken Takahashi, Yosuke Seto, Koutaroh Okada, Shinya Uematsu, Ken Uchibori, Mika Tsukahara, Tomoko Oh‐hara, Naoya Fujita, Noriko Yanagitani, Makoto Nishio, Kenichi Okubo, Ryohei Katayama   +11 more
doaj   +1 more source